Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noah Graham

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cancer|November 2, 2021
Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse eventsEdward H Ip, Santiago Saldana, Kathy D Miller, et al.
Blood Cancer Journal|April 2, 2022
Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patientsSamilia Obeng-Gyasi, Noah Graham, Shaji Kumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2023
Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 TrialNathaniel S O'Connell, Fengmin Zhao, Ju-Whei Lee, et al.
Cancer|October 22, 2025
Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatmentsJohn Devin Peipert, Shaili Ganatra, Fengmin Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2025
A phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancerFilipa Lynce, Noah Graham, Bose S Kochupurakkal, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancerAna C Garrido-Castro, Noah Graham, Lestat R Ali, et al.
JAMA Network Open|March 27, 2024
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple MyelomaJohn Devin Peipert, Fengmin Zhao, Ju-Whei Lee, et al.
The Lancet. Oncology|March 1, 2023
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trialSara M Tolaney, Paolo Tarantino, Noah Graham, et al.
JCO Oncology Practice|July 19, 2024
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)Adrienne G Waks, Emily L Chen, Noah Graham, et al.
Nature Communications|May 15, 2026
Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trialAna C Garrido-Castro, Noah Graham, Katelyn X Li, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer|November 2, 2021
Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse eventsEdward H Ip, Santiago Saldana, Kathy D Miller, et al.
Blood Cancer Journal|April 2, 2022
Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patientsSamilia Obeng-Gyasi, Noah Graham, Shaji Kumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2023
Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 TrialNathaniel S O'Connell, Fengmin Zhao, Ju-Whei Lee, et al.
Cancer|October 22, 2025
Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatmentsJohn Devin Peipert, Shaili Ganatra, Fengmin Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2025
A phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancerFilipa Lynce, Noah Graham, Bose S Kochupurakkal, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancerAna C Garrido-Castro, Noah Graham, Lestat R Ali, et al.
JAMA Network Open|March 27, 2024
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple MyelomaJohn Devin Peipert, Fengmin Zhao, Ju-Whei Lee, et al.
The Lancet. Oncology|March 1, 2023
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trialSara M Tolaney, Paolo Tarantino, Noah Graham, et al.
JCO Oncology Practice|July 19, 2024
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)Adrienne G Waks, Emily L Chen, Noah Graham, et al.
Nature Communications|May 15, 2026
Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trialAna C Garrido-Castro, Noah Graham, Katelyn X Li, et al.
Pageof 2